Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?-Reference-Cited by-同舟云学术

Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

Published:2019-12 Issue:12 Volume:37 Page:964-969
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Serretta Vincenzo,Valerio Maria Rosaria,Costa Renato,Tripoli Vincenzo,Murabito Alessandra,Princiotta Alessandro,Scalici Gesolfo Cristina^ORCID,Borsellino Nicolò,Verderame Francesco,Gebbia Vittorio,Licari Maria,Sanfilippo Chiara

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference21 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Metastatic prostate cancer and the bone: significance and therapeutic options;Gartrell;Eur Urol,2015

3. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer;Cornford;Eur Urol,2017

4. Current perspectives on bone metastases in castrate-resistant prostate cancer;Logothetis;Cancer Metastasis Rev,2018

5. Significant antitumor effect from bone-seeking, alpha-particle emitting (223)Ra demonstrated in an experimental skeletal metastases model;Henriksen;Cancer Res,2002

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SNMMI Procedure Standard/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases;Journal of Nuclear Medicine Technology;2023-06-14

2. Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study;Minerva Urology and Nephrology;2023-01